


INDICAID™ COVID-19 / Influenza A&B Antigen Test



Triple threat. One test.

Rapid detection of COVID-19, Influenza A, and Influenza B—all in 15 Minutes.



PRODUCT OVERVIEW

COVID-19/Influenza A&B Antigen Test

The COVID-19 / Influenza A&B point-of-care test offers fast, accurate, and actionable results for three respiratory viruses using a single nasal swab. Designed for point-of-care (POC) settings, it empowers clinical decision-making when timing matters most.


POC

Type	COVID-19 / Influenza A&B antigen test
Age	14+ or 2-13 with help from an adult
Sample type	Anterior nasal swab
Time to result	15 minutes
Pack size	25-test pack
Regulatory status	FDA De Novo: DEN240029
Shelf life	24 months (Contact sales for up to date expiry)




3:1

Detects COVID-19, Influenza A&B from a single nasal swab



Rapid results

Clear answers at just 15 minutes



Accurate

High sensitivity and specificity across all targets



Trusted tech

Based on a well-established lateral flow immunoassay platform

INDICAID™

Modern testing

A solution that supports fast, accessible diagnostics without added complexity

How it works



Swab each nostril gently



Stir swab in provided solution



Drop sample onto test device



Read results at 15 minutes

PROVIDER INSIGHTS

One test. Three targets. Clinical clarity.



- CLIA-waived for POC use
Use in urgent care, clinics, schools, and employer health programs
- Differentiates overlapping symptoms
Helps guide proper antiviral or isolation protocols
- No lab equipment required
Simple workflow with high accuracy
- Reduces diagnostic guesswork
Informs treatment plans to make faster, more confident decisions

Streamlined

A workflow with no instrumentation required

Ideal for POC*

Use in clinics, urgent care, schools, and employment health settings

Actionable insights

Supports timely triage and treatment decisions for respiratory symptoms



Who it's for

CLIA waived healthcare settings such as:

- Primary care and urgent care clinics
- School and campus health centers
- Workplace health screening programs
- Community testing events and mobile care
- Long-term care and congregate settings

Why offer this test

Combines COVID-19, Flu A & Flu B testing into a single, easy-to-use kit

CLIA-Waived with FDA-granted De Novo status for broad professional use

Supports timely clinical decisions with no lab delays

Helps manage patient flow during respiratory illness surges

Distributed by **STAT Technologies** 800-217-7828 | info@stat-technologies.com

This test has been granted a De Novo classification of Class II by the U.S. Food and Drug Administration (FDA) under 513(f) for the qualitative detection and differentiation of influenza A, and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly in anterior nasal swab samples from individuals with signs and symptoms of respiratory tract infection. This test is for use by individuals aged 14 years or older testing themselves, or adults testing individuals aged 2 years or older. *For use in POC or patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.